Deals this week: Kuros Biosciences, Suda, ProLynx
Swiss-based biotechnology company Kuros Biosciences intends to raise funds through the rights offering of shares of its common stock to raise between Sfr20.15m ($20.68m) and Sfr25m ($25.66m).
The shares will be offered in the price range from Sfr12.5 ($12.83) to Sfr15.5 ($15.91) a share.
The company has concurrently announced a public offering of shares, proceeds from which are intended to be used for the commercialisation of the company’s products, MagnetOS and Neuroseal.
Austrian drug delivery company Suda has signed a binding memorandum of understanding (MoU) to acquire Aluztra Bio’s global intellectual property relating to Anagrelide, an anti-cancer agent that reduces the level of platelets and its potentially non-toxic analogues.
Aluztra Bio is a biotechnology company based in the UK.
US-based biotechnology company ProLynx has partnered with Daiichi Sankyo, a Japanese pharmaceutical company.
The partnership is intended at evaluating the company’s drug delivery linker technology in the eye.
US-based biopharmaceutical company Celsion Corporation intends to raise $5.5m in gross proceeds through the private placement of two million shares of its common stock or pre-funded warrants in lieu thereof.
Priced at $2.75 a share, the placement is expected to be subscribed to by institutional investors.
The proceeds are intended to be used for general corporate purposes.